O’Malley et al. (O’Malley F , Chia S , Tu D , et al . Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy . J Natl Cancer Inst . 2009 ; 101 ( 9 ): 644 – 650) advocated a role for TOP2A alteration and HER2 amplification status in prediction of incremental benefit from anthracycline-based adjuvant chemotherapy in breast cancer. We believe that, with current evidence, it is inappropriate to conclude that anthracycline benefit may be predicted by HER2 and/or TOP2A status.
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy / Oakman C; Moretti E; Sotiriou C; Viale G; Di Leo A. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - ELETTRONICO. - (2009), pp. 1736-1737.
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
MORETTI, ERICA;
2009
Abstract
O’Malley et al. (O’Malley F , Chia S , Tu D , et al . Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy . J Natl Cancer Inst . 2009 ; 101 ( 9 ): 644 – 650) advocated a role for TOP2A alteration and HER2 amplification status in prediction of incremental benefit from anthracycline-based adjuvant chemotherapy in breast cancer. We believe that, with current evidence, it is inappropriate to conclude that anthracycline benefit may be predicted by HER2 and/or TOP2A status.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
